India's Bioeconomy: Charting a Course to Global Leadership

As per NITI Aayog’s ‘Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035’ released on 16^th July 2026, India stands at a defining juncture in what many call the biological century. With biotechnology poised to reshape medicine, agriculture, and manufacturing, the question is no longer whether India will participate in this shift, but whether it will lead it.

From Growth Story to Strategic Ambition

India's bioeconomy has expanded sixteen-fold in a decade, from $10 billion in 2014 to $195.3 billion in 2025, now contributing 4.8% of GDP.
This growth is no longer speculative; it rests on demonstrated capability, evident in India's pandemic-era vaccine leadership, over 10,000 biotech startups, and a globally trusted manufacturing base.
The roadmap argues that incremental progress is insufficient. It calls instead for mission-mode execution to scale the bioeconomy to $691 billion by 2035 and $2.6 trillion by 2047, generating over 30 million high-value jobs.

A Framework for Convergence

Central to this ambition is the BioE3 policy, anchoring Economy, Environment, and Employment as organising principles.
The strategy hinges on integrating AI, computational biology, and robotics with traditional biological research, moving India from fragmented programmes towards coordinated National BioMissions spanning gene therapies, climate-resilient agriculture, synthetic biology, and pandemic preparedness.

Institutional and Financial Scaffolding

The roadmap recommends empowered cross-ministerial governance, a national bio-data council, and a proposed ₹50,000-crore growth fund to bridge the "valley of death" between research and commercial scale.

Conclusion

Global competitors – the US, EU, and China – are already moving decisively. India's window to shape, rather than merely follow, the biological age remains open, but narrowing.